entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 00:14:24 - browse：19

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： The inclusion problem at the heart of rehabilitation research

knowledge

Wikipedia

WSS

Pumping milk in bathrooms at health conferences is common

Guardant Health colon cancer test endorsed by FDA advisory panel

New research sheds light on how often breast cancer is overdiagnosed

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Head of FDA's diagnostics center, who led through Covid, retires

The world needs the new pandemic treaty

knowledge

entertainment

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

There's an unseen cost to disruptive road

Supreme Court strikes down use of affirmative action

Why we need mandatory labeling of GMO products

Medical leaders decry Supreme Court decision on affirmative action

High breast density mammograms need follow

Activists slam private health insurers over coverage restrictions

CVS is on a mission to consolidate health care. Will it work?

Psychedelics group wrestles with new pharma identity

The world needs the new pandemic treaty

focus

Unmasking the 'centricity' illusion in clinical trials

The inclusion problem at the heart of rehabilitation research

Decentralized clinical trials need collaboration to achieve wider use

HPV vaccine, cervical cancer study delivers historic results

Pharma’s losing bet in New Jersey

Mass General, Mayo Clinic look to monetize custom

knowledge

Wikipedia

entertainment

explore